Scotland starts scrutiny of HCV-infected blood:
This article was originally published in Clinica
The Scottish government is to hold an inquiry to determine whether haemophiliacs who contracted hepatitis C from contaminated blood products should receive compensation. It recently emerged that the heat treatment used to kill off viruses in blood products in Scotland had not been applied at a sufficiently high temperature and the products may have remained contaminated for up to one year after the UK government had declared them safe in 1986. Unlike haemophiliacs who were infected with HIV, compensation from the UK government has so far been denied to those with hepatitis C.
You may also be interested in...
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
A recent Department of Health and Human Services proposal to review regulations every 10 years may mean good things for the device industry, said David Hoffmeister, partner, Wilson Sonsini Goodrich & Rosati.